BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23800523)

  • 1. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 2. "Personalizing" therapy for non-small cell lung cancer.
    D'Cunha J
    Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
    Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
    J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation sequencing applications in cancer research.
    Zhang W; Nykter M; Chen K
    Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
    Bernicker E
    Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
    Boutros PC; Pintilie M; John T; Starmans MH; Der SD; Shepherd FA; Tsao MS; Jurisica I
    J Natl Cancer Inst; 2010 Nov; 102(21):1677-8; author reply 1678-9. PubMed ID: 20921041
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
    Dacic S
    Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
    Gao W; Xu J; Shu YQ
    Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
    Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
    Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First clinically useful marker for lung cancer identified.
    Oncology (Williston Park); 2003 May; 17(5):737-8. PubMed ID: 12800797
    [No Abstract]   [Full Text] [Related]  

  • 13. [Non-small cell lung carcinoma: Perspectives for the twenty-first century?].
    Milleron B
    Presse Med; 2011 Apr; 40(4 Pt 1):368-70. PubMed ID: 21388779
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?
    Dubinett SM; Elashoff D; Meyerson M
    J Clin Oncol; 2004 Aug; 22(16):3209-11. PubMed ID: 15249586
    [No Abstract]   [Full Text] [Related]  

  • 15. The coming of age of molecular tumor profiling.
    Antonoff MB; D'Cunha J
    Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer biomarkers: present status and future developments.
    Cagle PT; Allen TC; Olsen RJ
    Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers for incidence, prognosis, and response to therapy.
    Tong BC; Harpole DH
    Surg Oncol Clin N Am; 2012 Jan; 21(1):161-75. PubMed ID: 22098838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
    Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
    Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in stage I of non-small-cell bronchial carcinoma].
    Passlick B; Pantel K
    Zentralbl Chir; 1996; 121(10):851-7; discussion 858-60. PubMed ID: 9019934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association of molecular biology of lung cancers and their metastasis and prognosis].
    Mao YS; Gao YN; He J
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):632-4. PubMed ID: 17236563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.